Back to Trials
NCT07654972PHASE1RecruitingAccepts Healthy Volunteers

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Eli Lilly and Company

Start Date

6/24/2026

Completion Date

4/1/2029

Summary

The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 35 to 45 weeks (7 to 11 months).

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease * Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m² * Have had a self-reported stable weight for 3 months prior to screening Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data * Is an individual of childbearing potential (IOCBP)

Interventions

DRUG

LY4174794

DRUG

LY4174794

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

ObesityOverweight

Locations

ICON Early Phase Services, LLC

San Antonio, Texas 78232

United States

ICON Early Phase Services, LLC

Salt Lake City, Utah 84124

United States

Lilly Centre for Clinical Pharmacology

Singapore, 138623

Singapore